Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ginkgo Bioworks Holdings ( (DNA) ) has shared an announcement.
On December 18, 2025, Ginkgo Bioworks announced that longtime co-founder and Chief Operating Officer Dr. Reshma Shetty will transition her COO responsibilities to CEO Dr. Jason Kelly and senior executive Jennifer Wipf, effective January 1, 2026. Dr. Shetty will remain President and a member of the Board and will concentrate on expanding and utilizing the company’s autonomous lab to deliver its cell engineering service offerings, while Dr. Kelly assumes the principal operating officer policymaking role and Wipf, formerly Chief Commercial Officer and General Manager for Discovery Solutions and Manufacturing, takes charge of day-to-day commercial and operational functions, including procurement, deployment, facilities, real estate, and people operations, reflecting a leadership realignment aimed at strengthening operations and commercial execution.
The most recent analyst rating on (DNA) stock is a Sell with a $8.50 price target. To see the full list of analyst forecasts on Ginkgo Bioworks Holdings stock, see the DNA Stock Forecast page.
Spark’s Take on DNA Stock
According to Spark, TipRanks’ AI Analyst, DNA is a Underperform.
Ginkgo Bioworks Holdings faces significant financial challenges with declining revenues and substantial losses, which are the most impactful factors in the overall score. Technical indicators also suggest a bearish outlook, and the negative P/E ratio reflects ongoing profitability issues. While strategic expansions and cost reductions are positive, they are insufficient to outweigh the current financial and technical weaknesses.
To see Spark’s full report on DNA stock, click here.
More about Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc. operates in the biotechnology sector, providing cell engineering services supported by an autonomous laboratory platform. The company focuses on using its advanced lab capabilities to design, develop, and scale engineered cells for a range of applications and customers.
Average Trading Volume: 1,360,512
Technical Sentiment Signal: Sell
Current Market Cap: $490.8M
See more data about DNA stock on TipRanks’ Stock Analysis page.